RGC
Regencell Bioscience Holdings Ltd
6.20$
+0.0%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Balance Sheet
Regencell Bioscience Holdings Ltd (RGC) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 5.8 million $. Tick rows to compare them in a chart.
Tick rows to compare them in a chart (up to 4)
| Line item | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,310 | 2,471 | 2,542 | 2,532 | 2,468 | 2,634 | 2,599 | 2,638 | 2,493 | 2,341 | 2,210 | 2,705 | 2,540 | 2,632 | 2,646 | 2,843 | 0.2 | 0.5 | 0.3 | 18 | 13 | 8.4 | 5.8 | |
| 389 | 376 | 321 | 262 | 241 | 525 | 273 | 429 | 347 | 404 | 258 | 465 | 341 | 438 | 447 | 463 | 0.2 | 0.4 | 0.1 | 16 | 12 | 8.1 | 4.9 | |
| 276 | 288 | 243 | 196 | 162 | 435 | 170 | 328 | 205 | 253 | 110 | 281 | 147 | 220 | 247 | 229 | 0.2 | 0.4 | 0.1 | 6.4 | 1.6 | 3.0 | 2.4 | |
| 276 | 288 | 243 | 196 | 162 | 435 | 170 | 328 | 211 | 253 | 110 | 288 | 151 | 220 | 247 | 229 | 0.2 | 0.4 | 0.1 | 16 | 12 | 8.0 | 4.9 | |
| – | – | – | – | – | – | – | 69 | – | 100 | 104 | 129 | – | 153 | 155 | 184 | – | – | 0.0 | 0.0 | 0.1 | 0.2 | – | |
| 6.0 | 6.0 | 7.0 | 7.0 | 8.0 | 8.0 | 8.0 | 12 | 15 | 15 | 18 | 19 | 18 | 22 | 21 | 23 | – | – | 0.0 | 0.0 | -0.1 | -0.2 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | 0.1 | 1.5 | – | – | – | |
| 227 | 197 | 213 | 223 | 214 | 181 | 178 | 179 | 179 | 179 | 268 | 320 | 320 | 329 | 327 | 346 | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 15 | 12 | 22 | 21 | 28 | 58 | 54 | 50 | 46 | 44 | – | – | – | – | – | – | – | |
| 1,036 | 1,673 | 2,471 | 2,501 | 2,489 | 2,753 | 2,841 | 2,885 | 2,983 | 2,912 | 2,906 | 3,418 | 3,434 | 3,510 | 3,485 | 3,699 | 2.1 | 3.2 | 4.3 | 0.9 | 0.6 | 0.2 | 0.9 | |
| 304 | 412 | 644 | 693 | 556 | 527 | 366 | 397 | 469 | 401 | 388 | 506 | 477 | 551 | 510 | 561 | 2.1 | 3.2 | 4.3 | 0.6 | 0.6 | 0.2 | 0.7 | |
| – | 47 | 56 | 68 | 52 | – | 77 | 17 | 96 | 21 | 22 | 30 | 27 | 27 | 26 | 27 | 2.1 | 3.1 | 3.7 | 0.4 | 0.4 | 0.1 | 0.3 | |
| 154 | 194 | 182 | 181 | 168 | 183 | 162 | 199 | 162 | 175 | 157 | 170 | 166 | 230 | 195 | 232 | – | – | – | – | – | – | – | |
| 1,274 | 798 | 71 | 31 | -21 | -119 | -242 | -247 | -490 | -571 | -697 | -713 | -895 | -878 | -839 | -856 | -1.8 | -2.7 | -4.0 | 17 | 12 | 8.2 | 4.9 | |
| 74 | 64 | 23 | 44 | 30 | 42 | 24 | 47 | 9.4 | 16 | 1.4 | 72 | 48 | 64 | 97 | 71 | -1.8 | -2.7 | -4.0 | -11 | -17 | -22 | -25 | |
| 5,628 | 5,408 | 5,665 | 154 | 50 | 219 | 44 | 5,856 | 5,872 | 155 | 5,890 | 5,917 | 5,940 | 5,947 | 5,958 | 5,965 | 480 | 480 | 480 | 494 | 494 | 494 | 494 |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.